Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30086172HIVENSG00000186716.21protein_codingBCRYesNo613P11274
TVIS30084988HIVENSG00000186716.21protein_codingBCRYesNo613P11274
TVIS30055183HIVENSG00000186716.21protein_codingBCRYesNo613P11274
TVIS30055184HIVENSG00000186716.21protein_codingBCRYesNo613P11274
TVIS30055185HIVENSG00000186716.21protein_codingBCRYesNo613P11274
TVIS30055186HIVENSG00000186716.21protein_codingBCRYesNo613P11274
TVIS30055187HIVENSG00000186716.21protein_codingBCRYesNo613P11274
TVIS20038778HPVENSG00000186716.21protein_codingBCRYesNo613P11274
TVIS20023449HPVENSG00000186716.21protein_codingBCRYesNo613P11274
TVIS44030081HTLV-1ENSG00000186716.21protein_codingBCRYesNo613P11274
TCGA Plot Options
Drug Information
GeneBCR
DrugBank IDDB08901
Drug NamePonatinib
Target IDBE0004743
UniProt IDP11274
Regulation Typeinhibitor
PubMed IDs23409026
CitationsIqbal Z, Aleem A, Iqbal M, Naqvi MI, Gill A, Taj AS, Qayyum A, ur-Rehman N, Khalid AM, Shah IH, Khalid M, Haq R, Khan M, Baig SM, Jamil A, Abbas MN, Absar M, Mahmood A, Rasool M, Akhtar T: Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era. PLoS One. 2013;8(2):e55717. doi: 10.1371/journal.pone.0055717. Epub 2013 Feb 8.
GroupsApproved; Investigational
Direct ClassificationBenzanilides
SMILESCN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1
PathwaysPonatinib Inhibition of BCR-ABL
PharmGKBPA165980594
ChEMBLCHEMBL1171837